Cover Page

Universiteit Leiden

Leiden University Repository

The handle http://hdl.handle.net/1887/29822 holds various files of this Leiden University dissertation.

Author: Timmers, Petra Jeanette
Title: Early ovarian cancer
Issue Date: 2014-10-16

Abbreviations
Curriculum Vitae
Publications
Authors and affiliations
Alphabetic order references

Abbreviations

AC	Adjuvant chemotherapy
ACTION	Adjuvant ChemoTherapy In Ovarian Neoplasm
CA 125	Cancer antigen 125
CCC	Clear cell carcinoma
DFS	Disease-free survival
EGSOG	European guidelines for surgical staging of ovarian cancer
EOC	Early ovarian cancer
EORTC	European Organisation for Research and Treatment of Cancer
EORTC-GCG	European Organisation for Research and Treatment of Cancer Gynecologic Cancer Group
FIGO	International Federation of Gynecology and Obstetrics
GICOG	Gruppo Interregionale Collaborative Oncology Group
GOG	Gynecologic Oncology Group
HR	Hazard ratio
ICON1	International Collaborative Ovarian Neoplasm 1
MMS	Multimodel screening
OS	Overall survival
RMI	Risk of malignancy index
SAC	Serous adenocarcinoma
UKCTOCS	UK Collaborative Trial of Ovarian Cancer Screening
USS	Ultrasound screening
WHO	World Health Organisation

Curriculum Vitae

Petra Jeanette Timmers is geboren op 14 juli 1966 te Katwijk. In 1984 behaalde zij haar eindexamen atheneum aan het Pieter Groen College te Katwijk. Zij begon in 1984 aan de studie geneeskunde aan de RU Leiden en behaalde in 1990 het doctoraal examen en in 1993 het artsexamen. Aansluitend werd zij AGNIO (assistent geneeskundige niet in opleiding) Gynaecologie en Verloskunde in het IJsselland Ziekenhuis te Capelle aan den IJssel en in 1994 in het Leids Universitair Medisch Centrum. Van 1995 tot 1997 was zij fellow bij de European Organisation for Research and Treatment of Cancer (EORTC) in Brussel. Met de opleiding Gynaecologie en Verloskunde begon zij op 1 juni 1997 in het Medisch Centrum Haaglanden te Den Haag (opleider prof. dr. P.J. Dörr †) en van 1998 tot 2002 in het Leids Universitair Medisch Centrum (opleiders prof. dr. H.H.H. Kanhai en mw. prof. dr. G.G. Kenter) en het laatste jaar in het Medisch Centrum Haaglanden. Na haar opleiding was zij chef de clinique in het Medisch Centrum Haaglanden te Den Haag en begon in 2005 als fellow gynaecologische oncologie in het Erasmus Medisch Centrum te Rotterdam. Sinds april 2008 is zij staflid in het Maasstad Ziekenhuis te Rotterdam met als subspecialisatie de gynaecologische oncologie. Zij is opleider vanaf april 2013.

Publications*

1. Kagie MJ, Kenter GG, Zomerdijk-Nooijen Y, Hermans J, Schuuring E, **Timmers PJ**, Trimbos JB, Fleuren GJ. Human papillomavirus infection in squamous cell carcinoma of the vulva, in various synchronous epithelial changes and in normal vulvar skin. *Gynecol Oncol* 1997; 67(2):178-183.

2. Favalli G, Therasse P, **Timmers P**, Oosterom AT van, Pecorelli S, Vergote I, Mulder P de. Quality control (QC) in multicentric trials (MCT)- The EORTC-GCCG experience (part II). *Int J Gyn Cancer* 1999; 9(1): 141.

3. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumulo S, **Timmers P**, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-placitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three year results. *J Natl Cancer Inst* 2000; 92(9): 699-708.

4. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, **Timmers P**, Coens C, Pecorelli S. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. *J Natl Cancer Inst* 2003; 95(2):113-25.

5. Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Tropé C, Nardi M, Kærn J, Tumulo S, **Timmers P**, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W. Long term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. *Int J Gynecol Cancer* 2003; 13: 144-148.

6. Trimbos JB, **Timmers P.** Chemotherapy for early ovarian cancer. *Curr Opin Obstet Gynecol* 2004; 16(1): 43-8.

7. Rustin GJ, **Timmers P**, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Eisenhauer E. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial cisplatin and paclitaxel versus cisplatin and cyclophosphamide. *J Clin Oncol* 2006; 24(1): 45-51.

*Publications from the author in this thesis and related topics

8. **Timmers PJ**, Zwinderman AH, Teodorovic I, Vergote I, Trimbos JB. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial. *Int J Gynecol Cancer* 2009; 19(1): 88-93.

9. Groenen SM, **Timmers PJ**, Burger CW. Recurrence rate in vulvar carcinoma in relation to pathological margin distance. *Int J Gynecol Cancer* 2010; 20(5): 869-873.

10. Trimbos B, **Timmers P**, Pecorelli S, Coens C, Ven K, van der Burg M, Casado A. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. *J Natl Cancer Inst* 2010; 102(13): 982-987.

11. **Timmers PJ**, Zwinderman AH, Coens C, Vergote I, Trimbos JB. Understanding the problem of inadequately staging early ovarian cancer. *Eur J Cancer* 2010; 46(5): 880-884.

12. **Timmers PJ**, Zwinderman AH, Coens C, Vergote I, Trimbos JB. Lymph node sampling and taking of blind biopsies are important elements of the surgical staging of early ovarian cancer. *Int J Gynecol Cancer* 2010; 20(7): 1142-1147.

13. **Timmers PJ**, Zwinderman AH, Coens C, Vergote I, Trimbos JB. Prognostic value of IC substages in invasive epithelial ovarian carcinoma. *Submitted*

14. Zaal A, Peyrot WJ, Berns PM, van der Burg ME, Veerbeek JH, Trimbos JB, Chadron I, van Diest PJ, van Wieringen WN, Krijgsman O, Meijer GA, Piek JM, **Timmers PJ**, Vergote I, Verheijen RH, Ylstra B, Zweemer RP; On behalf of the EORTC GCG Translational Research Group. *Cell Oncol (Dordr)* 2012; 35(3): 181-188.

Authors and affiliations

From the Department of Gynecology and Obstetrics, Maasstad Hospital, Rotterdam, The Netherlands; **Petra Timmers**

From the Department of Gynecology, Leiden University Medical Center, The Netherlands; **Baptist Trimbos**

From the Department of Gynecology and Obstetrics, University Hospital Gasthuisberg Leuven, Belgium; **Ignace Vergote**

From the Department of Biostatistics, Academic Medical Center, Amsterdam, The Netherlands; **Koos Zwinderman**

From the Data Center, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; **Corneel Coens, Koen Ven, Ivana Teodorovic, Livia Giurgea**

From the Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands; **Maria van der Burg** †

From the Department of Gynecology and Obstetrics, Universita di Brescia, Brescia, Italy; **Sergio Pecorelli**

From the Department of Medical Oncology, University Hospital San Carlos, Madrid, Spain; **Antonio Casado**

From the Department of Medical Oncology, University Hospital Antwerp, Belgium; **Jan Vermorken**

From the Department of Gynecology and Obstetrics, Istituto Mangiagalli and Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; **Giorgio Bolis, Giovanna Scarfone**

From the Department of Gynecology and Obsterics Ospedale San Gerardo, Monza, Italy; **Constantino Mangioni, Gerardo Zanetta**

From the Department of Medical Oncology Institut d'Oncologia Corachan, Barcelona, Spain; **Caterina Madronal**

From the Department of Gynecology and Obstetrics Ospedale di Circolo e Fondazione Macchi, Varese, Italy; **Massimo Franchi**

From the Department of Gynecology and Obstetrics Policlinico San Matteo, Pavia, Italy; **Saverio Tateo**

Alphabetic Order References

A

Ahmed FY, Wiltshaw E, A'Hern RP, et al. Natural history and prognososis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 2968-2975.

Andersen E, Knudsen A, Svarrer T, et al. The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. Gynecol Oncol 2005; 99: 552–556.

Announcement. Staging announcement : FIGO cancer committee. Gynecol Oncol 1986; 25:383-385.

Annual report on the results of treatment in carcinoma of the uterus, vagina and ovary. Kottmeier HL ed. 1973; 15: 15-18.

Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001; 22: 255-288.

Aure JC, Hoes K, Kolstad P. Clinical and histological studies of ovarian carcinoma. Long term follow up of 990 cases. Obstet Gynecol 1971; 37: 1-9.

Aure JC, Hoeg K, Kolstad P. Mesonephroid tumors of the ovary: clinical and histopathologic studies. Obstet Gynecol 1971; 37: 860-867.

B

Baak JPA, Langley FA, Talerman A, Delemarre JFM. Interpathologist and intrapathologist disagreement in ovarian grading and typing. Anal Quant Cytol Histol 1986; 8: 354-357.

Baiocchi G, Grosso G, Di Re E, et al. Systematic pelvic and paraaortic lymphadenectomy at second look laparotomy for ovarian cancer. Gynecol Oncol 1998; 69: 151-156.

Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998; 70: 255–258.

Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2006; 102: 432-439.

Benda JA, Zaino R. GOG pathology manual. Buffalo, NY: Gynecologic Oncology Group, 1994.

Benedetti-Panici P, Greggi S, Maneschi F, et al. Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. Gynecol Oncol 1993; 51: 150-154.

Bertelsen K, Holund B, Andersen JE, Nielsen K, Stroyer I, Ladehoff P. Prognostic factors and adjuvant treatment in early epithelial ovarian cancer. Int J Gynecol Cancer 1993; 3: 211-218.

Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol 1995; 6: 887–893.

Boylan KLM, Andesen JD, Anderson LB, Higgins L, Skubitz APN. Quantitative proteomic analysis by iTRAQ® for the identification of candidate biomarkers in ovarian cancer serum. Proteome Science 2010; 8: 31-39.

Bray F, Loos AH, Tognazzo S, La VC. Ovarian cancer in Europe: cross sectional trends in incidence of mortality in 28 countries, 1953-2000. Int J Cancer 2005; 113: 977-990.

Brescia RJ, Dubin N, Demopoulos RI. Endometrioid and clear cell carcinoma of the ovary. Factors affecting survival. Int J Gynecol Path 1989; 8: 132-138.

Bristow RE. Surgical standards in the management of ovarian cancer. Curr Opin Oncol 2000; 12: 474-480.

Brugghe J, Baak J, Wiltshaw E, Brinkhuis M, Meijer G, Fisher C. Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment. Gynecol Oncol 1998; 68: 47-53.

Brun JL, Feyler A, Chêne G, Saurel J, Brun G, Hocké C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000; 78: 21-27.

Burghardt E, Giardi F, Lahousen M, Tamassino K. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991; 40:103-106.

Buchsbaum HJ, Brady MF, Delgado G, et al. Surgical staging of carcinoma of the ovaries. Surg Gynecol Obstet 1989; 169: 226-232.

C

Cass I, Li AJ, Runowicz CD, Fields AB, et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 2001; 80: 56-61.

Chan J, Munro E, Cheung M, et al. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 2007; 109: 12-19.

Chan JK, Fuh K, Shin JY, et al. The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?. Br J Cancer 2008; 98: 1191-1196.

Chiari S, Rota S, Zanetta G, et al. Early-stage epithelial ovarian cancer: an overview. Forum (Genova) 2000; 10: 298–307.

Colombo N, Guthrie D, Chiari S, et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003; 95(2): 125–132.

Coukos G, Rubin SC. Early ovarian cancer. Curr Treat Options Oncol 2000; 1: 129-137.

Crawford SC. Do specialists do it better? Review of meta-analysis by Scotroc and Liberati data. In: du Bois A, Harper P, Kaye SB, editors. Perspectives in Gynecologic Oncology 2002; Munich, Germany. 9–10 November 2002. Apharetta, GA: Imedex. pp. 85–112.

Crozier MA, Copeland LJ, Silva EG, Gershenson DM, Stringer CA. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol 1989; 35: 199-203.

Czernobilsky B, Silverman BB, Enterline HT. Clear cell carcinoma of the ovary. A clinico-pathologic analysis of pure and mixed forms and comparison with endometrioid carcinoma. Cancer 1970; 25: 762-772.

D

Davy M, Stenwig AE, Kjorstad KE, et al. Early stage ovarian cancer: The effect of adjuvant treatment with a single alkylating agent. Acta Obstet Gynecol Scand 1985; 64: 531-532.

Dembo AJ, Bush RS, Beale FA, et al. The Princess Margaret Hospital study of ovarian cancer: Stages I, II, and asymptomatic III presentations. Cancer Treat Rep 1979; 63: 249-254.

Dembo A, Prefontaine M, Michel P, Bush RS. Prognostic factors in stage I epithelial ovarian carcinoma. Proc Am Soc Clin Oncol 1986; 5: 124.

Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjörstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990; 75: 263-273.

Dent SF, Klaassen D, Pater JL, et al. Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada–Clinical Trials Group (NCIC–CTG). Ann Oncol 2000; 11: 65–68.

Doshi N, Tobon H. Primary clear cell carcinoma of the ovary. An analysis of 15 cases and a review of the literature. Cancer 1977; 39: 2658-2664.

Dubeau L. The cell of origin of epithelial tumors and the ovarian surface dogma: does the emperor have no clothes? Gynecol Oncol 1999; 72 (3): 437-442.

E

Earle CC, Schrag D, Neville BA, et al. Effect of surgeon speciality on processes of care and outcomes for ovarian cancer. J Natl Cancer Instit 2006: 98: 151-154.

Einhorn N, Nilsson B, Sjövall K. Factors influencing survival in carcinoma of the ovary. Study from a well defined Swedish population. Cancer 1985; 55: 2019-2025.

Enakpene CA, Omigbodun AO, Goecke TW, Odukogbe AT, Beckmann MW. Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index. J Obstet Gynaecol Res 2009; 35: 131–138.

Engelen MJ, Kos HE, Willemse PH, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006; 106: 589-598.

F

Faught W, Le T, Fung Kee Fung M, et al. Early ovarian cancer: what is the staging impact of retroperitoneal node sampling? J Obstet Gynaecol Can 2003; 25: 18–21.

Favalli G, Odicino F, Torri V, et al. Early stage ovarian cancer: the Italian contribution to clinical research. An update. Int J Gynecol Cancer 2001; 11: 12–19.

Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidences and mortality in Europe 2008. Eur J Cancer 2010; 46: 765-781.

FIGO Committee on Gynecologic Oncology. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet 2000; 70: 209-262.

Fine G, Clarke HD, Horn RC. Mesonephroma of the ovary. A clinical, morphological, and histogenic appraisal. Cancer 1973; 31: 398-410.

Finn CB, Luesley DM, Buxton EJ, et al. Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. Br J Obstet Gynaecol 1992; 99: 54-58.

G

Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60: 412-417.

Gorai I, Nakazawa T, Miyagi E, Hirahara F, Nagashima Y, Minaguchi H. Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastic lesions with different properties. Gynecol Oncol 1995; 57(1): 33-46.

Grönroos M, Nieminen U, Kauppila A, et al. A prospective, randomized, national trial for treatment of ovarian cancer: The role of chemotherapy and external irradiation. Eur J Obstet Gynecol Reprod Biol 1984; 17: 33-42.

H

Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer 2007; 17: 1238-1244.

Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J Gynaecol Obstet 2006; 95(S1): S161-S192.

Helewa ME, Krepart GV, Lotocki R. Staging laparotomy in early epithelial ovarian carcinoma. Am J Obstet Gynecol 1986; 154: 282-286.

Hensley ML, Castiel M, Robson ME. Screening for ovarian cancer: what we know, what we need to know. Oncology 2000; 14 (11): 1601-1607.

Hernandez E, Bhagavan BS, Parmley TH, Rosenshein NB. Interobserver variability in the interpretation of epithelial ovarian cancer. Gynecol Oncol 1984; 17: 117-123.

Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000; 19: 3-10.

Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 1994; 55: S91-96.

Hreshchyshyn MM, Park RC, Blessing JA, et al. The role of adjuvant therapy in Stage I ovarian cancer. Am J Obstet Gynecol 1980; 138: 139-145.

I

International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand 1971; 50: 1-7.

International Federation of Gynecology and Obstetrics. FIGO news. Int J Gynecol Obstet 1971; 9: 178-179.

Ioka A, Tsukuma H, Ajiki W, Oshima A. Influence of hospital procedure volume on ovarian cancer survival in Japan, a country with low incidence of ovarian cancer. Cancer Sci 2004; 95: 233-237.

Itamochi H, Kigawa J, Sugiyama T, et al. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002; 100(2): 281-287.

J

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun J. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-249.

Jenison EL, Montag AG, Griffiths CT, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989; 32: 65-71.

Jones HW. Recent advances in gynecologic cancer. Bull Sloane Hosp Wom NY 1965; 11: 33.

K

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

Kawai M, Kikkawa F, Hattori S, Ohta M, Arii Y, Tomoda Y. Long-term follow-up of patients with epithelial carcinoma of the ovary. Int J Gynaecol Obstet 1994; 44: 259-266.

Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989; 32: 342-349.

Kita T, Kikuchi Y, Kudoh K, et al. Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncology reports 2000; 7: 327-331.

Knapp R, Friedmann E. Aortic lymphnode metastases in early ovarian cancer. Am J Obstet Gynecol 1974; 119: 1013-1017.

Kodoma S, Tanaka K, Tokunaga A, Sudo N, Takahashi T, Matsui K. Multivariate analysis of prognostic factors in patients with ovarian cancer stage I and II. Int J Gynaecol Obstet 1997; 56: 147-153.

Kohn EC, Azad N, Annunziata C, Dhamoon AS, Whiteley G. Proteomics as a tool for biomarker discovery. Dis Markers 2007; 23: 411-417.

Kojs Z, Glinski B, Reinfuss M, et al. Results of a randomized prospective trial comparing postoperative abdominopelvic radiotherapy with postoperative chemotherapy in early ovarian cancer [in French]. Cancer Radiother 2001; 5: 5–11.

Kommoss S, Harter P, Traut A, et al. Compliance to Consensus Recommendations, Surgeon's Experience, and Introduction of a Quality Assurance and Management Program; Influence on Therapy of Early-Stage Ovarian Carcinoma. Int J Gynecol Cancer 2009; 19(4): 787-793.

Kottmeier HL. Presentation of therapeutic results of treatment in carcinoma of the femeale pelvis: experience of the annual report on the results of treatment in carcinoma of the uterus, vagina and ovary. Gynecol Oncol 1976; 4: 16-18.

Krafft W, Morack G, Flach W, et al. The therapy of early ovarian cancer (T1/2M0N0). Arch Geschwulstforsch 1980; 50 (7): 664-671.

Kurman RJ, Shih I. Pathogenesis of ovarian cancer. Lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008; 27: 151-160.

L

Le T, Adolph A, Krepart G, Lotocki R, Heywood M. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol 2002; 85: 351–355.

Lentz S, Cha S, Wieand H, Podratz K. Stage I epithelial carcinoma: Survival analysis following definitive treatment. Gynecol Oncol 1991; 43: 198-202.

Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clininical impact. J Clin Oncol 2008; 26 (32): 5284-5293.

Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Cancer mortality in Europe 1995-1999 and an overview of trends since 1960. Int J Cancer 2004; 110: 155-169.

M

Maggioni A, Benedetti Panici P, Dell'Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 2006; 95: 699-704.

Mangioni C, Bolis G, Molteni P, Belloni C. Indications, advantages, and limits of laparoscopy in ovarian cancer. Gynecol Oncol 1979; 7: 47-55.

Mayer AR, Chambers SK, Graves, et al. Ovarian staging: does it require a gynecologic oncologist? Gynecol Oncol 1992; 47: 223-227.

Mc Gowan L, Lesher LP, Norris HJ, Barnett M. Misstaging of ovarian cancer. Obstet Gynecol 1985; 65: 568–572.

Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer screening (UKCTOCS). The Lancet Oncology 2009; 10(4): 327-340.

Meyers MA. The spread and localization of acute peritoneal effusions. Radiology 1970; 95: 547-554.

Meyers MA. Distribution of intra-abdominal malignant seeding; dynamics of flow of ascitic fluid. Am J Roentgenol Radium Ther Nucl Med 1973; 119: 198-206.

Mizuno M, Kikkawa F, Shibata K, et al. Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture. Oncology 2003; 65: 29-36.

Monk BJ. Treatment of early-stage epithelial ovarian cancer. Am J Oncol Rev. 2003; 2(5): 244–247.

Montag AG, Jenison EL, Griffiths CT, Welch WR, Lavin PT, Knapp RC. Ovarian clear cell carcinoma. A clinicopathologic analysis of 44 cases. Int J Gynecol Pathol 1989; 8(2): 85-96.

Morice P, Wicart-Poque F, Rey, et al. Results of conservative treatment in epithelial ovarian carcinoma. Cancer 2001; 92: 2412–2418.

Morice P, Joulie F, Camatte S, et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 2003; 197(2): 198-205.

Mujezinoviç F, Takac I. Pelvic lymph node dissection in early ovarian cancer: success of retrieval of lymph nodes by individual lymph node groups in respect to pelvic laterality. Eur J Obstet Gynecol Reprod Biol 2010; 151 (2): 208-211.

Munoz KA, Harlan LC, Trimble EL. Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 1997; 15: 3408–3415.

Musemeci R, Banfi A, Bolis G, et al. Lymphangiography in patients with ovarian cancer epithelial cancer. Cancer 1977; 40: 1444-1449.

Mutch D. Surgical management of ovarian cancer. Semin Oncol 2002; 29: 3–8.

N

Nasu K, Hirota Y, Kawano Y, Matsui N, Hayata T, Miyakawa I. Characterization of intraoperative rupture of epithelial ovarian cancer at early stage. Nippon Sanka Fujinka Gakkai Zasshi 1995; 47: 907-910.

Negishi H, Takeda M, Fujimoto T, et al. Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early ovarian cancer. Gynecol Oncol 2004; 94: 161-166.

Nickles Fader A, Rose P. Role of surgery in ovarian carcinoma. J Clin Oncol 2007; 25: 2873–2883.

Norris HJ, Robinowitz M. Ovarian adenocarcinoma of mesonephric type. Cancer 1971; 28: 1074-1081.

Nguyen HN, Averette, HE, Hoskins W, et al. National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer 1993; 72: 3007-3011.

O

O'Brien ME, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 1993; 49: 250-254.

Ohkawa D, Amasaki H, Terashima Y, et al. Clear cell carcinoma of the ovary. Light and electron microscopic studies. Cancer 1977; 40: 3019-3029.

Olaitan A, Murdoch J, Weeks J. The management of women with apparent early ovarian cancer in the South-West region of England. J Obstet Gynaecol 2002; 22: 394–398.

Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT, Hellman S, Rosenberg DA, eds. Cancer: principles and practice oncology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2001; 1597-1632.

P

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2005; 55: 74-108.

Paulsen T, Kærn J, Tropé C. Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery. Gynecol Oncol 2011; 122(1): 83-88.

Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 104: 103-104.

Petru E, Lahousen M, Tamussino K, et al. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol 1994; 170: 656-662.

Pettersson F (ed.). Annual report on the results of treatment in gynecological cancer. International Federation of Gynecology and Obstetrics. Int J Gynecol Oncol 1991; 36 (suppl): 1-315.

Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol 2004; 191: 18-32.

Piver MS, Barlow JJ, Lele SB. Incidence of subclinical metastasis in stage I and II ovarian carcinoma. Obstet Gynecol 1978; 52: 100–104.

Piver MS, Malfetano J, Baker TR, Hempling RE. Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. Gynecol Oncol 1992; 46(3): 357-360.

Pothuri B, Leitao MM, Levine DA, et al. Genetic analysis of the early natural history of epithelial ovarian carcinoma. PloS One 2010; 5: e10358.

Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009; 104: 177-178.

R

Radisavljevic SV. The pathogenesis of ovarian inclusion cysts and cystomas. Obstet Gynecol 1977; 49: 424-429.

Recio FO, Piver MS, Hempling RE, Driscoll DL. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum–based chemotherapy. Cancer 1996; 78: 2157-2163.

Redman CW, Mould J, Warwick J, et al. The West Midlands epithelial ovarian cancer adjuvant chemotherapy trial. Clin Oncol 1993; 5: 1-5.

Rubin SC, Wang GY, Curtin JP, et al. Platinum based chemotherapy of high risk stage I epithelial ovarian cancer following comprehensive surgical staging. Obstet Gynaecol 1993; 82: 143-147.

Russel P. The pathologic assessment of ovarian neoplasms. Introduction to the common "epithelial" tumors and analysis of benign "epithelial" tumors. Pathology 1979; 11: 5-26.

S

Sainz de la Cuesta R, Goff BA, Fuller AF Jr, Nikrui N, Eichhorn JH, Rice LW. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol 1994; 84(1): 1-7.

Sakuragi N, Yamada H, Oikawa M, et al. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0). Gynecol Oncol 2000; 79: 251-255.

Saphir O, Lackner JE. Adenocarcinoma with clear cells (hypernephroid) of ovary. Surg Gynecolog Obstet 1944; 79: 539-543.

Schiller W. Mesonephroma ovarii. Am J Cancer 1939; 35: 1-21.

Schueler JA, Cornelisse CJ, Hermans J, Trimbos JB, van der Burg MEL, Fleuren GJ. Prognostic factors in well-differentiated early-stage epithelial ovarian cancer. Cancer 1993; 71: 787-795.

Schueler JA, Trimbos JB, Hermans J, Fleuren GJ. The yield of surgical staging in presumed early stage ovarian cancer; benefits or doubts? Int J Gynecol Cancer 1998; 8: 95–102.

Scully RE. Pathology of ovarian cancer precursors. J Cell Biochem Suppl 1995; 23: 208-218.

Seidman JD. Pathology of borderline (low malignant potential) ovarian tumours. Best Pract Res Clin Obstet Gynaecol 2002; 16: 499-512.

Serov SF, Scully RE, Sobin LH. Histological Typing of Ovarian Tumours. In International Histological Classification of Tumours, no 9. Geneva, World Health Organization, 1973: 17-54.

Sevalda P, Gitsch E, Dittrich C, et al. Therapeutic and prognostic results of a prospective multicenter ovarian study of FIGO stages I and II. Geburtshilfe Frauenheilkd 1987; 47: 179-185.

Sevalda P, Dittrich C, Salzer H. Prognostic value of capsule rupture of the capsule in stage I epithelial ovarian carcinoma. Gynecol Oncol 1989; 35: 321-322.

Shevchuk MM, Monsanto BW, Fenoglio CM, Richart RM. Clear cell carcinoma of the ovary: A clinicopathologic study with review of the literature. Cancer 1981; 47: 1344-1351.

Shimada M, Kigawa J, Kanamori Y, et al. Outcome of patients with early ovarian cancer undergoing three courses of adjuvant chemotherapy following complete surgical staging. Int J Gynecol Cancer 2005; 15: 601-605.

Sigurdsson K, Johnsson JE, Tropé C. Carcinoma of the ovary, stages I and II: A prospective randomized study of the effects of postoperative chemotherapy and radiotherapy. Ann Chir Gynaecol 1982; 71: 321-329.

Sigurdsson K, Alm P, Gullberg B. Prognostic factors in malignant epithelial ovarian tumors. Gynecol Oncol 1983; 15: 370-380.

Silverberg SG. Histopathologic grading of ovarian carcinoma; a review and proposal. Int J Gynecol Pathol 2000; 19: 7-15.

Sjövall K, Nilsson B, Einhorn N. Different types of rupture of the tumor capsule and the impact on survival in early ovarian carcinoma. Int J Gynecol Cancer 1994; 4(5): 333-336.

Soper JT, Johnson P, Johnson V, Berchuck A, Clarke-Pearson DL. Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma. Obstet Gynecol 1992; 80: 949-953.

Staging announcement. FIGO Cancer Committee. Gynecol Oncol 1986; 50: 383–385.

Stalsberg H, Abeler V, Blom GP, Bostad L, Skarland E, Westgaard G. Observer variation in histologic clasification of malignant and borderline ovarian tumors. Hum Pathol 1988; 19: 130-135.

Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary. Cancer 2000; 88: 2584-2589.

Suzuki M, Ohwada M, Yamada T, et al. Lymph node metastasis in stage I epithelial ovarian cancer. Gynecol Oncol 2000; 79: 305-308.

Swenerton KD, Hilsop TG, Spinelli J, Le Riche JC, Yang N, Boyes DA. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 1985; 65: 264-270.

T

Takeshima N, Hirai Y, Umayahara K, et al. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. Gynecol Oncol 2005; 99: 427-431.

Tammela J, Geisler JP, Eskew PN Jr, Geisler HE. Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur J Gynaec Oncol 1998; 19: 438-440.

Thigpen JT. Limited stage ovarian carcinoma. Semin Oncol 1999; 26: 29-33.

Tingulstad S, Skjeldestad FE, Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol 2003; 102(3): 499–505.

Travis LB, Holoway EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999; 340: 351–357.

Travis LB, Curtis RE, Boice JD Jr., Platz CE, Hankey BF, Fraumeni JF Jr. Second malignant neoplasm's among long-term survivors of ovarian cancer. Cancer Res. 1996; 56(7): 1564–1570.

Trimbos JB, Schueler JA, Lent M van, Hermans J, Fleuren GJ. Reasons for incomplete surgical staging in early ovarian carcinoma. Gynecol Oncol 1990; 37: 374–377.

Trimbos JB, Schueler JA, van der Burg M, et al. Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer. Cancer 1991; 7: 597-602.

Trimbos JB, Bolis G. Guidelines for surgical staging of ovarian cancer. Obstet Gynecol Surv 1994; 49: 814-816.

Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95(2): 105-112.

Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003; 95: 113–125.

Trimbos JB, Vergote I. Response [letter]. J Natl Cancer Inst 2003; 95: 64–65.

Trimbos JB, Zanaboni F. Some afterthoughts on two recent randomized European trials in early ovarian cancer. Am J Oncol Rev. 2003; 2(5): 228–239.

Trimbos JB, Timmers P. Chemotherapy for early ovarian cancer. Curr Opin Obstet Gynecol 2004; 16(1): 43-48.

Trimbos B, Timmers P, Pecorelli S, et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst 2010; 102(13): 982-987.

Tropé C, Kærn J, Hogberg T, et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 2000; 11: 281-288.

U

Ulusoy S, Akbayir O, Numanoglu C, Ulusoy N, Odabas E, Gulkilik A. The risk of malignancy index in discrimination of adnexal masses. Int J Gynaecol Obstet 2007; 96: 186-191.

V

Van Calster B, Timmerman D, Bourne T, et al. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus CA-125. J Natl Cancer Instit 2007; 99: 1706-1714.

Vergote I, Kærn J, Abeler VM, Pettersen EO, De Vos LN, Tropé CG. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 1993; 169 (1): 40-52.

Vergote I, de Brabander J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357: 176-182.

Vergote I, Trimbos JB. Treatment of patients with early epithelial ovarian cancer. Curr Opin Oncol. 2003; 15(6): 452–455.

Verleye L, Ottevanger PB, van der Graaf W, et al., on behalf of the Gynaecological Cancer Group (GCG) of the European Organisation for Research and Treatment of Cancer (EORTC). EORTC-GCG process quality indicators for ovarian cancer surgery. Eur J Cancer 2009; 45: 517-526.

Vernooij F, Heintz P, Witteveen E, van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologist and in specialized hospitals: a systematic review. Gynecol Oncol 2007; 105: 801-812.

Vernooij F, Heintz AP, Witteveen PO, van der Heiden-van der Loo M, Coebergh JW, van der Graaf Y. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study. J Natl Cancer Inst 2008; 100: 399-406.

Vernooij F, Heintz AP, Coebergh JW, Massuger LF, Witteveen PO, van der Graaf Y. Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol Oncol 2009; 112: 455-461.

Villa A, Parazzini F, Acerboni S, Guarnerio P, Bolis G. Survival and prognostic factors of early ovarian cancer. Br J Cancer 1998; 77: 123-124.

Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Research 2008; 14: 1065-1072.

W

Walter A, Magrina J. Contralateral pelvic and aortic lymph node metastasis in clinical stage I epithelial ovarian cancer. Gynecol Oncol 1999; 74: 128-129.

Webb MJ, Decker DC, Mussey E, Williams TJ. Factor influencing survival in Stage I ovarian cancer. Am J Obstet Gynecol 1973; 116: 222-228.

Wester JP, de Valk HW, Nieuwenhuis HK, et al. Risk factors for bleeding during treatment of acute venous thromboembolism. Thromb Haemost 1996; 76: 682–688.

Winter-Roach B, Hooper L, Kitchener H. Systematic review of adjuvant therapy for early
stage (epithelial) ovarian cancer. Int J Gynecol Cancer 2003; 13: 395-404.

Wu PC, Qu JY, Lang JH, Huang RL, Tang MY, Lian LJ. Lymph node metastasis of ovarian cancer: a preliminary survey of 74 cases of lymphadenectomy. Am J Obstet Gynecol 1986; 155: 1103-1108.

Y

Yasuda M, Nakabayashi Y, Isonishi S, et al. A study on factors influencing survival in stage I ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi 1985; 37: 1191-1196.

Yoonessi M, Weldon D, Satchidand SK, Crickard K. Clear cell ovarian adenocarcinoma. J Surg Oncol 1984; 27: 289-297.

Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA 1983; 250(22): 3072-3076.

Young RC. Initial therapy for early ovarian carcinoma. Cancer 1987; 60: 2042-2049.

Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322: 1021-1027.

Young RC. The treatment of early stage ovarian cancer. Semin Oncol 1995; 22: 76-79.

Young RC, Knapp FC, Fuks Z, Disaia PJ. Cancer of the ovary. In: De Vita V, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2001. P. 1083–1117.

Z

Zanetta G, Rota S, Chiari S, et al. The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis. Ann Oncol 1998; 9(10): 1097-1101.

Zanetta G, Chiari S, Rota S, et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol 1997; 104: 1030–1035.